The status of nuclear medicine techniques in the diagnosis of bone metastases in breast cancer.
In this article, the authors present their experience with the diagnosis of bone metastases in patients with breast cancer using bone scintigraphy with 99mTc phosphonate and radioimmunological determination of carcinoembryonic antigen (CEA) and tissue polypeptic antigen (TPA). In a group of 395 patients, there was agreement between tumour markers (CEA, TPA) and the results of bone scintigraphy in 331 cases (84%)--negative in 193 cases (49%) and positive (i.e. in terms of bone scintigraphy results and the presence of at least one tumour marker) in 138 cases (35%). On the basis of this good agreement of the results between bone scintigraphy and CEA and TPA levels, the authors recommend the following algorithm in monitoring patients with breast cancer: follow-up of tumour markers at several-month intervals and, any increase in their levels will refer the patient to further examination using imaging techniques including bone scintigraphy.
Makaiová
I
I
School of Medicine, Comenius University, Bratislava.
Kausitz
J
J
Hupka
S
S
Michaliková
B
B
Vivodová
M
M
Bohunický
L
L
D014408:Biomarkers, Tumor / Q000097:blood; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary*; D001842:Bone and Bones / Q000000981:diagnostic imaging*; D001943:Breast Neoplasms / Q000000981:diagnostic imaging* / Q000276:immunology; D002272:Carcinoembryonic Antigen / Q000032:analysis; D005260:Female; D006801:Humans; D013669:Technetium Tc 99m Medronate; D014055:Tomography, Emission-Computed
D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D013669:Technetium Tc 99m Medronate